Bryxta Bevacizumab 400mg Injection

Bryxta Bevacizumab 400mg Injection Specification

Grade
Pharma

Dosage
100 mg

Storage
Dry Place

Usage
Hospital

Appearance
Liquid

Bryxta Bevacizumab 400mg Injection Trade Information

Minimum Order Quantity
100 Packs

Supply Ability
5000 Packs Per Month

Delivery Time
7 Days

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

About Bryxta Bevacizumab 400mg Injection

Step into the spotlight with Bryxta Bevacizumab 400mg Injection-a sterling choice for hospitals seeking outstanding cancer care solutions. Crafted by Zydus and exported across India, this pharmaceutical-grade injection features a resplendent liquid formulation at a dosage of 100mg/4ml. Tailored for colon, lung, glioblastoma, and renal-cell carcinomas, each vial is secured with a package insert, ensuring uncompromised efficacy. Limited stock available-jump on this exceptional oncology treatment and equip your institution with the reliability and innovation your patients deserve.

Advantages and Applications of Bryxta Bevacizumab 400mg Injection

Bryxta Bevacizumab 400mg Injection offers targeted intervention against colon, lung, brain (glioblastoma), and kidney cancers. Its outstanding intravenous liquid formulation supports consistent results in hospital settings. Suitable for prescription-based administration by medical professionals, this pharmaceutical-grade treatment is designed for use in specialty and multispecialty institutions. The carefully engineered application media ensures precision dosing and extensive therapeutic benefit, catering to both newly-diagnosed and recurrent cancer cases in clinical environments.

Payment Terms and Export Excellence for Bryxta Bevacizumab 400mg Injection

Bryxta Bevacizumab 400mg Injection is available to global clients at a premium sale price with favorable payment terms. Shipments are managed through reliable FOB ports in India, ensuring secure freight and timely delivery. With a reputation as a leading exporter and wholesaler, we maintain high-quality standards for international markets, including Asia, Africa, and the Middle East. Jump on exclusive opportunities for procurement and experience an outstanding transaction process with every order.

Specification

Packaging Size	1 Vial and package insert
Brand	Bryxta
Composition	Bevacizumab
Manufacturer	Zydus
Treatment	For colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Prescription/Non prescription	Prescription
Form	Injection
Dose	100 mg/4 ml
Usage	For intravenous infusion

FAQ's of Bryxta Bevacizumab 400mg Injection:

Q: How is Bryxta Bevacizumab 400mg Injection administered in clinical settings?

A: This injection is given through intravenous infusion under the supervision of qualified healthcare professionals, following standard hospital protocols.

Q: What cancers can be treated using Bryxta Bevacizumab 400mg Injection?

A: It is indicated for the treatment of colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma, providing a versatile solution for oncological care.

Q: When should the Bryxta Bevacizumab 400mg Injection be stored and handled with care?

A: The injection should always be stored in a dry place and kept under recommended conditions specified by the manufacturer to maintain product efficacy.

Q: Where is Bryxta Bevacizumab 400mg Injection manufactured and exported from?

A: Manufactured by Zydus, the product is exported and wholesaled from India to various international markets, ensuring widespread accessibility.

Q: What is the packaging size of Bryxta Bevacizumab 400mg Injection supplied to hospitals?

A: Each order includes 1 vial accompanied by a package insert, supporting clear guidance for safe and effective administration.

Q: How does Bryxta Bevacizumab 400mg Injection benefit hospital oncology departments?

A: The outstanding formulation and proven efficacy provide hospital departments with a reliable, advanced therapeutic option for managing multiple cancer indications.